C3a 70-77
Need Assistance?
  • US & Canada:
    +
  • UK: +

C3a 70-77

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

C3A (70-77) is an octapeptide corresponding to the COOH terminal of C3A, shows C3a specificity and 1-2% bioactivity.

Category
Peptide Inhibitors
Catalog number
BAT-010550
CAS number
63555-63-5
Molecular Formula
C35H61N13O10
Molecular Weight
823.94
C3a 70-77
IUPAC Name
(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid
Synonyms
Complement 3a (70-77); H-Ala-Ser-His-Leu-Gly-Leu-Ala-Arg-OH; L-alanyl-L-seryl-L-histidyl-L-leucyl-glycyl-L-leucyl-L-alanyl-L-arginine; (2S,5S,8S,14S,17S,20S,23S)-17-((1H-imidazol-4-yl)methyl)-23-amino-2-(3-guanidinopropyl)-20-(hydroxymethyl)-8,14-diisobutyl-5-methyl-4,7,10,13,16,19,22-heptaoxo-3,6,9,12,15,18,21-heptaazatetracosan-1-oic acid; C3a octapeptide
Purity
≥95%
Density
1.44±0.1 g/cm3 (Predicted)
Sequence
ASHLGLAR
Storage
Store at -20°C
Solubility
Soluble in DMSO
InChI
InChI=1S/C35H61N13O10/c1-17(2)10-23(46-32(55)25(12-21-13-39-16-42-21)47-33(56)26(15-49)48-28(51)19(5)36)30(53)41-14-27(50)44-24(11-18(3)4)31(54)43-20(6)29(52)45-22(34(57)58)8-7-9-40-35(37)38/h13,16-20,22-26,49H,7-12,14-15,36H2,1-6H3,(H,39,42)(H,41,53)(H,43,54)(H,44,50)(H,45,52)(H,46,55)(H,47,56)(H,48,51)(H,57,58)(H4,37,38,40)/t19-,20-,22-,23-,24-,25-,26-/m0/s1
InChI Key
LYTNSBOBASKUDN-GUQPKPMOSA-N
Canonical SMILES
CC(C)CC(C(=O)NC(C)C(=O)NC(CCCN=C(N)N)C(=O)O)NC(=O)CNC(=O)C(CC(C)C)NC(=O)C(CC1=CN=CN1)NC(=O)C(CO)NC(=O)C(C)N
1. Suppression of humoral immune responses by synthetic C3a peptides
T E Hugli, B W Erickson, E L Morgan, W O Weigle, K F Fok J Immunol . 1983 Nov;131(5):2258-61.
Synthetic oligopeptides based on the COOH-terminal sequence of native human C3a were examined for the ability to suppress antigen-specific and polyclonal antibody responses. The synthetic peptides were found to qualitatively mimic the suppressive actions of human C3a, but proved to be less active on a molar basis. Comparison of the activity of the peptides with native C3a indicates that the most potent peptide is C3a 57-77 with C3a 65-77, C3a 70-77, C3a[Ala 71,72]70-77, and C3a 73-77 being less active, respectively. These results indicate that the region of the C3a molecule responsible for immunosuppression is located in the COOH region.
2. Modulation of human lymphocyte function by C3a and C3a(70-77)
D E Trentham, D G Payan, E J Goetzl J Exp Med . 1982 Sep 1;156(3):756-65. doi: 10.1084/jem.156.3.756.
Human C3a and the synthetic octapeptide C3a (70-77), which retains the activities of an anaphylatoxin, inhibit in a concentration-dependent manner the generation of leukocyte inhibitory factor (LIF) activity by human mononuclear leukocytes and T lymphocytes cultured with the mitogens phytohemagglutinin (PHA) or concanavalin A (Con A) or the antigen streptokinase-streptodornase (SK-SD). The generation of LIF activity was inhibited by 50% by 10(-8) M C3a or C3a(70-77) with PHA or Con A as the stimulus, whereas a more than 10-fold higher concentration of C3a(70-77) than C3a was required to achieve the same level of suppression with SK-SD as the stimulus. Similar concentrations of C3a(70-77) inhibited to the same extent the migration of T lymphocytes stimulated by alpha-thioglycerol of Con A. Neither C3a nor C3a(70-77) altered significantly the uptake of [3H]thymidine by human mononuclear cells exposed to PHA, Con A, or SK-SD. The capacity of C3a(70-77)-Sepharose,m but not Sepharose alone, to adsorb or inactivate mononuclear leukocytes required for the generation of LIF activity established a direct interaction. Analysis of the lymphocytes in the effluent from C3a(70-77)-Sepharose columns, using monoclonal antibodies to surface antigens, showed a selective depletion of the helper/inducer population of lymphocytes. C3a might represent an important mediator of the functionally selective regulation of human T lymphocyte activities by the complement system.
3. Identification of casoxin C, an ileum-contracting peptide derived from bovine kappa-casein, as an agonist for C3a receptors
A Shiota, H Suganuma, M Yoshikawa, F Tani, M Takahashi, K Kurahashi, S Moriguchi, R Sasaki, H Usui Peptides . 1997;18(3):329-36. doi: 10.1016/s0196-9781(97)00044-2.
Casoxin C (Tyr-Ile-Pro-Ile-Gln-Tyr-Val-Leu-Ser-Arg) is a bioactive peptide that was isolated from a tryptic digest of bovine kappa-casein as an anti-opioid peptide in longitudinal strips of guinea pig ileum. Casoxin C also evokes contraction of the ileal strips, and we found that this process was biphasic with rapid and slow components. The contractile profile was very similar to that of human complement C3a(70-77), which is the COOH-terminal octapeptide of C3a and has, although less potent, qualitatively the same biological activities as C3a. Casoxin C also has homology with C3a(70-77). The rapid contraction was mediated by histamine release and the slow contraction was mediated by a prostaglandin E2-like substance, judging from the effects of various pharmacological inhibitors and antagonists on the ileal contraction. Casoxin C had affinity for C3a receptors (IC50 = 40 microM) in the radioreceptor assay. In addition, casoxin C showed phagocyte-stimulating activities. Casoxin C is therefore the first milk-derived peptide identified, that acts through complement C3a receptors.
Online Inquiry
Verification code
Inquiry Basket